New Approaches Look Good for Cardiovascular Disease

By McCann, Jean | Drug Topics, December 6, 1999 | Go to article overview

New Approaches Look Good for Cardiovascular Disease


McCann, Jean, Drug Topics


Reports of some exciting new drug approaches to treating cardiovascular disease, based on clinical trials, marked this year's meeting of the American Heart Association, held in Atlanta.

Among the clinical efforts was HOPE (Heart Outcomes Prevention Evaluation). The trial showed a 22% relative risk reduction in heart attack, stroke, and death from cardiovascular disease in those taking the ACE inhibitor Altace (ramipril, Hoechst Marion Roussel) 10 mg/ day, compared with placebo. Another arm of the study randomized patients to 400 mg daily of vitamin E or placebo; no advantage was shown for vitamin E at that point in time.

HOPE, begun in 1994, involved 267 centers in 19 countries, including the United States, Canada, Europe, and South America. Not quite half of the patients were hypertensive, but benefits of the drug were seen in the normotensives as well, according to study chairman Salim Yusuf, M.D., professor of medicine at McMaster University in Hamilton, Ontario. Most amazing to him, he said, was that significantly fewer people developed diabetes in the rampipril group, suggesting this as a powerful new way to prevent the disease. This was the largest prevention trial ever involving diabetics, who made up about 40% of the group. A three-year follow-up study is planned.

"The beauty of this trial is that the results follow other proven therapies, like beta-blockers, statins, aspirin, calcium-channel blockers, or diuretics. I think all high-risk diabetics, such as those over 50-55 or who have eye disease or microalbuminuria, should take this drug," he said.

In addition to the good results with diabetes, the relative risk reduction for the ramipril group as a whole in coronary angioplasty, coronary artery bypass grafting, and peripheral angioplasty was 15%, compared with placebo. A three-year follow-up study is anticipated.

Other trials, involving about 6,000 patients, heralded a new approach to the treatment of cardiovascular disease. The first of a new drug class, the vasopeptidase inhibitor omapatrilat (Vanlev, Bristol-Myers Squibb) was shown to be superior to another antihypertensive now on the market-especially in reducing systolic hypertension, an important risk factor for stroke and death. The new drug, which inhibits the enzyme vasopeptidase, involves the simultaneous inhibition of neutral endopeptidase and angiotensin-converting enzyme. The resulting decrease in vascular tone lowers blood pressure. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA 8, MLA 7, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Note: primary sources have slightly different requirements for citation. Please see these guidelines for more information.

Cited article

New Approaches Look Good for Cardiovascular Disease
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen
Items saved from this article
  • Highlights & Notes
  • Citations
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA 8, MLA 7, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Search by... Author
    Show... All Results Primary Sources Peer-reviewed

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.